Publication:
Smokers having Activating EGFR Mutant Non-Small Cell Lung Cancer Might Benefit from EGFR-TKI Treatment - Single-Center Experience

Simple item page
dc.contributor.authorDANE, FAYSAL
dc.contributor.authorsErcelep, Ozlem; Telli, Tugba Akin; Alan, Ozkan; Hasanov, Rahib; Simsek, Eda Tanrikulu; Babacan, Nalan Akgul; Kaya, Serap; Kaya, Handan; Dane, Faysal; Yumuk, Perran Fulden
dc.date.accessioned2022-03-14T10:08:04Z
dc.date.available2022-03-14T10:08:04Z
dc.date.issued2020
dc.description.abstractOBJECTIVE This study aims to evaluate the predictive impacts of cigarette smoking on treatment outcomes of EGFR tyrosine kinase inhibitors (TKIs) in Non-Small Cell Lung Cancer (NSCLC) patients with activating EGFR mutations. METHODS We retrospectively evaluated the data of 46 patients with metastatic NSCLC (adenocarcinoma) and EGFR mutation (exon 19 deletion, exon 21 mutation, and exon 18 activating mutation) treated with EGFR-TKI between 2012 and 2017. RESULTS Median age was 61 (range 30-80), and 56.5% (26/46) was female. Median follow-up was 39 months. The rate of smoking was 41.3% (19/46). The EGFR mutations were present in the patients, exon 19 deletion in 29 patients (64%), exon 21 mutation in 13 patients (28%) and exon 18 activating mutations in four patients (8%). Progression-free survival (PFS) was 21 months in smokers, whereas it was 25 months in non-smokers (p=0.330). Median PFS was 21 months for patients using EGFR-TKI in the first-line (35 patients), and 13 months in the second-line setting (11 patients). CONCLUSION There were no statistically significant PFS differences between the smoker and non-smoker groups. Smokers should be tested for EGFR mutations, as some patients may benefit from EGFR TKI treatment for longer than reported in the literature.
dc.identifier.doi10.5505/tjo.2020.2207
dc.identifier.issn1300-7467
dc.identifier.urihttps://hdl.handle.net/11424/244099
dc.identifier.wosWOS:000565170700013
dc.language.isoeng
dc.publisherKARE PUBL
dc.relation.ispartofTURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectEpidermal growth factor receptor
dc.subjectsmoking
dc.subjecttyrosine kinase inhibitors
dc.subjectGROWTH-FACTOR-RECEPTOR
dc.subjectOPEN-LABEL
dc.subjectNEVER SMOKERS
dc.subject1ST-LINE TREATMENT
dc.subjectCIGARETTE-SMOKING
dc.subjectGENE-MUTATIONS
dc.subjectPHASE-III
dc.subjectGEFITINIB
dc.subjectCHEMOTHERAPY
dc.subjectRESISTANCE
dc.titleSmokers having Activating EGFR Mutant Non-Small Cell Lung Cancer Might Benefit from EGFR-TKI Treatment - Single-Center Experience
dc.typearticle
dspace.entity.typePublication
local.avesis.id6b8922da-c39c-4ab7-bd88-95ec3849a65a
local.import.packageSS16
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atTRDIZIN
local.journal.numberofpages6
oaire.citation.endPage339
oaire.citation.issue3
oaire.citation.startPage334
oaire.citation.titleTURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY
oaire.citation.volume35
relation.isAuthorOfPublication059ce50a-8d16-4fc6-a86c-85c9baa19a5c
relation.isAuthorOfPublication.latestForDiscovery059ce50a-8d16-4fc6-a86c-85c9baa19a5c

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ercelep - 2020 - Smokers having Activating EGFR Mutant Non-Small Ce.pdf
Size:
177.09 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs